Lupin seeks to invalidate patent on Bausch & Lomb eye drug
Thursday, July 21, 2016
Indian generic drugmaker Lupin Ltd is asking a court to invalidate a patent on Bausch & Lomb Inc's anti-inflammatory eye drug Prolensa as it seeks to make a generic version of the drug.
Lupin's claim, filed Monday in the U.S. District Court for the District of New Jersey, comes in response to a patent infringement lawsuit Bausch & Lomb and Senju Pharmaceutical Co Ltd, which owns the patent, filed in February.
Source : reuters.com
